Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist under development for obesity and metabolic liver disease. In phase 2 trials, once-weekly dosing produced dose-dependent weight loss of 12.5-14.9% versus placebo over 46 weeks.
Appetite Regulation
Peptides mimic satiety hormones, reducing hunger signals from the brain.
Quickstart Highlights
- Dosage: 0.6-6mg
- Frequency: Weekly
- Administration: Subcutaneous
- Cycle length: Ongoing
Dosing Plan
| Weeks | Dose | Units |
|---|---|---|
| Weeks 1–2 | 0.6mg once weekly | 12 units (0.12mL) |
| Weeks 3–4 | 1.2mg once weekly | 24 units (0.24mL) |
| Weeks 5–6 | 2.4mg once weekly | 48 units (0.48mL) |
| Weeks 7–12+ | 4.8-6.0mg once weekly | 96-120 units |
How to mix
Add 2.0mL bacteriostatic water per 10mg vial → 5mg/mL concentration
- Draw 2.0mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall.
- Gently swirl until dissolved.
- Label with date and refrigerate at 2–8°C.
Syringe Math Reference
- 10mg vial with 2mL BAC water = 5 mg/mL
- 1 unit = 0.01mL = 50mcg
- 0.6mg = 12 units
- 2.4mg = 48 units
- 4.8mg = 96 units
What you'll need
Survodutide Vials (10mg)
- 4 weeks 1 vial
- 8 weeks 2 vials
- 12 weeks 3-4 vials
Insulin Syringes (U-100)
- 12 weeks 12 syringes
Bacteriostatic Water (10mL)
- 12 weeks 1 bottle
Alcohol Swabs
- 12 weeks 1 × 100-count box
How This Works
Survodutide is a dual agonist that activates both GLP-1 and glucagon receptors. This dual mechanism promotes weight loss through multiple pathways: GLP-1 activation reduces appetite and slows gastric emptying, while glucagon activation increases energy expenditure and promotes hepatic fat mobilization. The combination shows promise for both obesity and metabolic liver disease.
Mechanism of Action
How Survodutide Works in Your Body
Peptide Administered
Enters bloodstream and travels to target receptors
Brain Signaling
Binds to GLP-1 receptors in the hypothalamus
Appetite Reduced
Signals satiety — you feel full sooner
Fat Metabolism
Body shifts to burning stored fat for energy
Benefits & Side Effects
Potential Benefits
- Significant weight loss (12.5-14.9% in trials)
- Liver fat reduction
- Potential MASH/NASH treatment
- Enhanced energy expenditure
- Improved metabolic parameters
Potential Side Effects
- Nausea (common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- Injection site reactions
How to store it
- Lyophilized: Freeze at ≤−20°C.
- Reconstituted: Refrigerate at 2–8°C.
- Protect from light.
Good to know
- Phase 2 trials showed 12.5-14.9% weight loss vs placebo.
- Also being developed for MASH/NASH treatment.
- GLP-1/glucagon dual agonist mechanism.
- Gradual titration over 10-12 weeks required.
- Currently in clinical development.
References
Community Insights
Summarised from 2 sourcesSurvodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist under development for obesity and metabolic liver disease. In phase 2 trials, once-weekly dosing produced dose-dependent weight loss of 12.5-14.9% versus placebo over 46 weeks. Gradual titration over 10-12 weeks. Also
Common Dosages Reported
- 0.6-6mg Weekly
- Standard protocol dosing
Side Effects Mentioned
- Generally mild, individual variation expected
- See full guide for detailed safety info
Stacking Suggestions
- Consult research and healthcare provider before stacking
What people are saying
Results vary based on individual response
Consistent dosing and timing important
Reviews & Discussion
Real experiences shared by the community — not medical advice.
Seeking Survodutide After Anxiety from Retatrutide
A user inquired about Survodutide as an alternative after experiencing significant anxiety while attempting to use Retatrutide. They are seeking a peptide that offers metabolic benefits without the psychological side effects associated with triple-agonist compounds.
Transitioning to Survodutide for Weight Loss
A user shared their intention to switch to Survodutide after experiencing moderate results with Tirzepatide and severe gastrointestinal side effects from Semaglutide. They expressed optimism that the dual glucagon and GLP-1 receptor agonist profile of Survodutide would provide a smoother weight loss experience.
No discussion yet — be the first.
No notes yet — be the first.